Production, characterisation, and in vitro nebulisation performance of budesonide-loaded PLA nanoparticles

被引:9
作者
Amini, Mohammad Ali [1 ]
Faramarzi, Mohammad Ali [2 ,3 ]
Gilani, Kambiz [4 ]
Moazeni, Esmaeil [4 ]
Esmaeilzadeh-Gharehdaghi, Elina [5 ]
Amani, Amir [5 ,6 ]
机构
[1] Islamic Azad Univ, Fac Vet Med, Dept Microbiol, Karaj Branch, Karaj, Iran
[2] Univ Tehran Med Sci, Biotechnol Res Ctr, Tehran 14174, Iran
[3] Univ Tehran Med Sci, Fac Pharm, Dept Pharmaceut Biotechnol, Tehran 14174, Iran
[4] Univ Tehran Med Sci, Sch Pharm, Dept Pharmaceut, Aerosol Res Lab, Tehran 14174, Iran
[5] Univ Tehran Med Sci, Sch Adv Technol Med, Dept Med Nanotechnol, Tehran 14174, Iran
[6] Univ Tehran Med Sci, Med Biomat Res Ctr, Tehran 14174, Iran
关键词
Budesonide; in vitro deposition; nanosuspension; nebuliser; PLA nanoparticles; DRUG-DELIVERY; PHYSICOCHEMICAL CHARACTERIZATION; EPITHELIAL-CELLS; RELEASE; FORMULATION; DEPOSITION; SIZE; NANOPRECIPITATION; PHARMACOKINETICS; NANOSPHERES;
D O I
10.3109/02652048.2013.871358
中图分类号
O69 [应用化学];
学科分类号
081704 ;
摘要
The aim of this study is to prepare a nanosuspension of budesonide for respiratory delivery using nebuliser by optimising its particle size and characterising its in vitro deposition behaviour. PLA (poly lactic acid)-budesonide nanosuspension (BNS) was prepared using high-pressure emulsification/solvent evaporation method. To optimise particle size, different parameters such as PLA concentration, sonication time, and amplitude were investigated. Fourier transform infrared spectroscopy (FTIR), differential scanning calorimetry (DSC), and scanning electron microscope (SEM) analyses were performed to characterise the prepared PLA-budesonide nanoparticles. The in vitro aerodynamic characteristics of the PLA-BNS using a jet nebuliser were estimated and compared with that of commercially available suspension formulation of budesonide. Budesonide-loaded PLA nanoparticles with fine particle size (an average size of 224-360 nm), narrow size distribution, and spherical and smooth surface were prepared. The optimum condition for preparation of fine particle size for aerosolisation was found to be at PLA concentration of 1.2 mg/ml and amplitude of 70 for 75 s sonication time. The in vitro aerosolisation performance of PLA-BNS compared to that of commercial budesonide indicated that it has significantly (p<0.05) smaller mass median aerodynamic diameter (MMAD) value with an enhancement in fine particle fraction (FPF) value. Improving the in vitro deposition of budesonide, PLA-BNS could be considered as a promising alternative suspension formulation for deep lung delivery of the drug using nebuliser.
引用
收藏
页码:422 / 429
页数:8
相关论文
共 44 条
[1]  
Almeziny M, 2007, J PHARM PHARMACOL, V59, pA28
[2]  
Amani A, 2010, AAPS PHARMSCITECH, P1
[3]   Alternatives to Conventional Suspensions for Pulmonary Drug Delivery by Nebulisers: A Review [J].
Amani, Amir ;
Amini, Mohammad Ali ;
Ali, Hany S. M. ;
York, Peter .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2011, 100 (11) :4563-4570
[4]   Evaluation of supercritical fluid engineered budesonide powder for respiratory delivery using nebulisers [J].
Amani, Amir ;
Chrystyn, Henry ;
Clark, Brian J. ;
Abdelrahim, Mohamed E. ;
York, Peter .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 2009, 61 (12) :1625-1630
[5]   Modeling the Parameters Involved in Preparation of PLA Nanoparticles Carrying Hydrophobic Drug Molecules Using Artificial Neural Networks [J].
Amini, Mohammad Ali ;
Faramarzi, Mohammad Ali ;
Mohammadyani, Dariush ;
Esmaeilzadeh-Gharehdaghi, Elina ;
Amani, Amir .
JOURNAL OF PHARMACEUTICAL INNOVATION, 2013, 8 (02) :111-120
[6]   Pulmonary targeting of sustained release formulation of budesonide in neonatal rats [J].
Arya, Vikram ;
Coowanitwong, Intira ;
Brugos, Boglarka ;
Kim, Won-Seok ;
Singh, Rajiv ;
Hochhaus, Guenther .
JOURNAL OF DRUG TARGETING, 2006, 14 (10) :680-686
[7]   Monodisperse hydrophilic polymer microspheres having carboxylic acid groups prepared by distillation precipitation polymerization [J].
Bai, Feng ;
Yang, Xinlin ;
Li, Rui ;
Huang, Bo ;
Huang, Wenqiang .
POLYMER, 2006, 47 (16) :5775-5784
[8]   Budesonide reduces vascular endothelial growth factor secretion and expression in airway (Calu-1) and alveolar (A549) epithelial cells [J].
Bandi, N ;
Kompella, UB .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2001, 425 (02) :109-116
[9]  
Bennett W.D., 1997, Ann. Occup. Hyg, V41. Supplement 1, P497
[10]  
Berg EB, 2009, RESP CARE, V54, P1671